Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SpaceX Dragon Lift-off. Video. WSJournal/YouTube.
PLCM. no iHub mod. Good PRs today.
http://ih.advfn.com/p.php?pid=squote&symbol=plcm
LLY. Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS)
http://finance.yahoo.com/news/lilly-announces-detailed-results-phase-171500971.html
GRFS. Dosed in Phase II Trial of Alpha-1 HC Aerosol to Treat Cystic Fibrosis
http://finance.yahoo.com/news/grifols-announces-first-patient-enrolled-155800737.html
SPPI. Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent
FOLOTYN® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009
FOLOTYN net sales were approximately $50 million in 2011
Spectrum acquired FOLOTYN through acquisition of Allos Therapeutics on September 5, 2012
http://finance.yahoo.com/news/spectrum-pharmaceuticals-announces-uspto-granted-110000705.html
GTXI. GTx to Present Scientific Poster Presentations on Enobosarm to Prevent and Treat Muscle Wasting in Cancer Patients
http://finance.yahoo.com/news/gtx-present-scientific-poster-presentations-110000824.html
PCRX. EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management
http://finance.yahoo.com/news/exparel-foundation-multimodal-regimen-achieves-103000770.html
RBCC. Amarantus Biosciences and RBCC Announce NuroPro Parkinson's Diagnostic as Target for Joint Venture
http://finance.yahoo.com/news/amarantus-biosciences-rbcc-announce-nuropro-090000051.html
The Afters - Light up the Sky - Video with Lyrics
nice landing, my dad would be so proud. he was so impressed by the ability to travel into space.
SpaceX Dragon launch, the "After Hours" feature tonight. iBox.
Nice xero90!
RXL sorry
Dogs of the Dow update.
http://www.dogsofthedow.com/dogytd.htm
SpaceX Dragon. Sunday 10/7/12
Seeking/Alpha-Weekend-Recap: ACAD, AEZS, AMRN, ARNA, ARQL, SNTA, SRPT.
http://seekingalpha.com/article/908681-weekend-recap-biotech-madness
The last trading week (October 1st through October 5) has been very interesting indeed. Here is a recap of some of the biggest stories, and some implications for the upcoming week:
The highlight of the week, Sarepta Therpaeutics (NASDAQ: SRPT), saw very boring trading until Wednesday morning, when news of its flagship drug Eteplirsen came out and sent shares soaring 200% higher. These phase IIb results gave indication that the drug was able to significantly slow the progress of Duchenne Muscular Dystrophy, which is especially exciting, since there are no cures or effective treatments for the disease. While there is growing talk of a potential FDA approval with just phase IIb trials, SRPT gave back about 24% in the last two trading sessions on profit-taking. Adam Feuerstein cites a $400-500 million market potential in the US, which would make Sarepta fairly undervalued - especially with more slide in the stock price.
Synta Pharmaceuticals (NASDAQ: SNTA) also broke a new 52-week high on phase IIb results for its flagship compound ganetespib (with docetaxel). This compound is showing a lot of promise in non-small cell lung carcinoma, although it seems that the hype over the new results has been factored in already. Overbought conditions imply that profit taking may overwhelm the exhausted bulls, although the longer term trend looks great. This is exactly what happened with Arena Pharmaceuticals (NASDAQ: ARNA), which seemed to lose its recent buying momentum on Thursday. This was made worse by a fresh underperform rating from Credit Suisse.
Also making news in non-small cell lung cancer is the discontinuation of phase III trials for ArQule's (NASDAQ: ARQL) ARQ 197 - also called tivantinib. This was recommended by their data monitoring committee, which crunched the numbers and figured that the drug wasn't going to meet its primary endpoint. Due to the disappointing news ARQL got crunched by 56% on Tuesday. Trading has been very volatile, but not completely directionless. ARQL is moving back up due to some faithful buyers, while we see shorts lightening their positions to capture gains.
Amarin (NASDAQ: AMRN), probably the most watched name in bio-tech besides the giants, has seen interesting activity as well. Trading was tame until we saw a downgrade from Wedbush, which was based on frustration over the NCE status of flagship drug Vascepa. In addition to this, fading speculation over big pharma acquisition/partnership with Amarin seems to be weighing on the stock. Still, based on valuation (and the sheer size of the cardiovascular drug market), the bullish motto is now "stay long, stay strong". The same could be said about ACADIA Pharmaceuticals (NASDAQ: ACAD), which broke a new 52-week high on Friday in anticipation of phase III results for its Parkinson's Disease Psychosis drug pimavanserin that are due in a few weeks. The stock actually suffered from a brief breakdown in late Friday trading, which erased most of Thursday's big rally, but this seems likely to be reversed.
Concluding the recap, we have AEterna Zentaris (NASDAQ: AEZS) which performed its reverse 1:6 stock split on Friday in order to regain compliance with NASDAQ trading stanadards. Investors continue to push the shares lower due to apprehension about future share dilution, which is reflected by the stock's 26% decline this week. AEZS will probably trade on this theme for quite some time
CLIR needs a moderator. I just can't go do it.
http://investorshub.advfn.com/Clearsign-Combustion-Corp-CLIR-24955/
StocksDiva Bio-Bin. FDA Target dates to Oct 29th. and chart links.
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/
10/29/2012
Cornerstone Therapeutics Inc. CRTX
CRTX 080 (NDA)
FDA decision on CRTX 080 for treatment of hyponatremia
http://stockcharts.com/h-sc/ui?s=CRTX&p=W&yr=0&mn=10&dy=0&id=p98537415266
10/27/2012
United Therapeutics Corp UTHR
UT-15C Treprostinil Diethanolamine Sustained Release Tablets (NDA)
FDA decision on Treprostinil for pulmonary arterial hypertension
http://stockcharts.com/h-sc/ui?s=UTHR&p=W&yr=0&mn=10&dy=0&id=p19857067596
10/23/2012
Hyperion Therapeutics, Inc. HPTX
Ravicti (NDA)
FDA decision on Ravicti for treatment of urea cycle disorder
http://stockcharts.com/h-sc/ui?s=HPTX&p=W&yr=0&mn=10&dy=0&id=p43085630433
10/21/2012
Impax Laboratories Inc IPXL
IPX066 (NDA)
FDA decision on IPX066 for treatment of idiopathic Parkinson's disease
http://stockcharts.com/h-sc/ui?s=IPXL&p=W&yr=0&mn=10&dy=0&id=p69460166375
10/19/2012
Supernus Pharmaceuticals, Inc. SUPN
SPN-804 (NDA)
FDA decision on SPN-804 for epilepsy
http://stockcharts.com/h-sc/ui?s=SUPN&p=W&yr=0&mn=10&dy=0&id=p70809143664
10/16/2012
Santarus Inc. SNTS
UCERIS (NDA)
FDA decision on UCERIS for induction of remission of mild to moderate active ulcerative colitis
http://stockcharts.com/h-sc/ui?s=SNTS&p=W&yr=0&mn=10&dy=0&id=p15528194029
U.S. EQUITIES WEEK AHEAD: Two Major Financials, Nine IPOs, Small Biz Data
www.foxbusiness.com/news/2012/10/05/us-equities-week-ahead-two-major-financials-nine-ipos-small-biz-data/
-What if it were possible to prevent harmful emissions from the combustion of any fuel, including gas, biomass, coal — even tire-derived fuel and municipal solid waste — in the flame, before those pollutants were ever formed?
http://www.clearsign.com/
I love a good question.
Nice work
CLIR. DD Sheet.
8,752,015 shares of common stock, par value $.0001, issued and outstanding.
10-Q 8/6/12
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8752959
-ClearSign's new technology that promises to improve key performance characteristics of industrial combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. ECC™ can be used anywhere there is a flame, regardless of fuel type, in the world’s commercial, industrial and utility combustion systems.
10/4/12. Seeking Alpha. Clearsign: A Potential World Changer Of A Stock
http://seekingalpha.com/article/904701-clearsign-a-potential-world-changer-of-a-stock
Read more: http://community.nasdaq.com/News/2012-10/clearsign-a-potential-world-changer-of-a-stock.aspx?storyid=179121#ixzz28SLe1HuX
-What if it were possible to prevent harmful emissions from the combustion of any fuel, including gas, biomass, coal — even tire-derived fuel and municipal solid waste — in the flame, before those pollutants were ever formed?
http://www.clearsign.com/
Electrodynamic Combustion Control™ Technology. How it works:
ClearSign’s Electrodynamic Combustion Control technology introduces computer-controlled high-voltage (but very low power) electric fields to manipulate the movement of electrically charged molecules (ions) that are a natural product of the combustion process. This pulsed field creates very powerful electrostatic forces (body forces) within the flame and the surrounding gas cloud. These forces can be manipulated to precisely control flame shape and the transfer of heat to, through, or away from a surface as desired. Because we can selectively target and mobilize specific charged molecules, our technology provides an unprecedented level of precision for optimizing combustion chemistry to suppress formation of pollutants at the flame source.
http://www.clearsign.com/technology/
Video presentaion of the technology. The Future of Fire.
http://vimeo.com/47543326
Includes these lab videos.
Radience. Flame Attachment. Heat Rejection.
Particle Control. Thermal Efficiency.
http://www.clearsign.com/technology/videos/
Applications:
Natural-gas fired boilers. PetroChemical processing.
PetroChemical processing.
Industrial sold fuels. Coal-fired power generation.
9/27/12 ClearSign Achieves Major Development Milestone: Demonstrates Technique to Provide Unprecedented Flame Stability up to 1,000,000 Btus per hour.
http://ih.advfn.com/p.php?pid=nmona&article=54323541
iHub. No moderator. http://ih.advfn.com/p.php?pid=squote&symbol=CLIR
WebSite. http://www.clearsign.com/
Company news. http://ir.stockpr.com/clearsigncombustion/company-news
FAQ. http://ir.stockpr.com/clearsigncombustion/faq
Management team. http://www.clearsign.com/our-team/
Chart at new-volume resistance.
Updating chart link.
http://stockcharts.com/h-sc/ui?s=CLIR&p=W&yr=1&mn=0&dy=0&id=p94483738206
Caledonia Mining Corporation Blanket Gold Mines mine workers
very HAPPY they have become part owners of the mines -
Caledonia Mining Corp. CALVF makes a Great Mission -
CALVF keeping 1000 workers and their families with
food and good housing, school, medical etc.
the spinn off help 10000 People with food or
they know - vs. not much from mugabe -
Blanket Gold Mine - Photographic Tour 2011 -
http://www.caledoniamining.com/pdfs/CALPres12062011.pdf
Operated of CALVF Blanket Gold Mines -
CALEDONIA #1 SCOTTISH RIGHT WAY TO GO -
http://www.caledoniamining.com/pdfs/CALPres08142012.pdf
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79661979
Mugabenomics' From Zimbabwe To The UK - "Gold Is Good"
Currency Ranked Returns – GBP in Fiat and Precious Metals In Last 5 Years
Gold continues to hover near its 11 month high in dollar terms and
near new records and the €1,400 level in euro terms.
The lack of confidence over Spain’s finances has kept investors
alert as they await a US jobless report on Friday to ascertain
just how poorly the US economy is. Recent data suggests that the
US economy is in a recession and may be on the verge of a
Depression.
http://www.zerohedge.com/news/2012-10-03/mugabenomics-zimbabwe-uk-gold-good
The strike in the gold mining sector continues to put a halt
to 39% of the nation’s sizeable gold output.
This is supporting gold.
NEWSWIRE
(Bloomberg) -- Gold Fields Workers at KDC Throw Fire Bombs as Strikes Persist
Gold Fields Ltd., South Africa’s second-biggest producer of the metal, said striking workers at the KDC West mine threw fire bombs at cars after about 1,000 assembled at the site. There were no “hospitalized injuries.”
The workers gathered late yesterday after being instructed to vacate hostels that had become “lawless and violent,” Sven Lunsche, a spokesman for Johannesburg-based Gold Fields, said today by mobile phone. The company applied for a court order to evict them after they failed to leave their accommodation.
Unofficial strikes have spread across South Africa’s mining industry since a six-week stoppage at Lonmin Plc resulted in pay increases of as much as 22 percent. Walkouts have also suspended sites owned by AngloGold Ashanti Ltd., South Africa’s largest gold miner, and Anglo American Platinum Ltd., where its Union operation is the latest to be disrupted, it said late yesterday.
Gold Fields workers have been on strike at KDC West since Sept. 9, cutting output by about 1,400 ounces a day, and have also downed tools at the Beatrix site. A judicial inquiry into the deaths of 44 people at Lonmin’s Marikana mine started this week.
(Bloomberg) – South Africa Platinum Mines May Cut 8,000 Jobs
Platinum companies in South Africa, which produces three-quarters of global supply, may cut more than 8,000 jobs as striking workers demand wage gains from cash- strapped employers, SBG Securities Ltd. said.
Worker pay increases will inflate costs, weighing on “already unsustainable industry margins,” analysts Justin Froneman and Walter de Wet said today in a note. Annual earnings may fall by about 65 percent, while employment may drop to about 176,650 next year from 184,890 last year, they said.
Strikes have spread through South Africa’s mining industry since workers at Impala Platinum Holdings Ltd. downed tools at the start of the year. Impala has since raised pay twice, while a stoppage and violent protests at Lonmin Plc resulted in wage increases of as much as 22 percent. Strikes have also disrupted Anglo American Platinum Ltd., the largest producer of the metal.
Higher wages mean about two-thirds of the platinum industry could be cash-negative next year when taking into account planned capital spending, Deutsche Bank AG said today in a note. While strikes drove up platinum prices by 21 percent in the past two months, the demand outlook has weakened, the bank said.
A stoppage that began at Anglo American Platinum’s Rustenburg mines in North West Province has spread to the company’s Union mine in Limpopo Province, it said today in a statement. Workers refused to go underground and handed a memorandum to management, it said, without disclosing workers’ demands.
Platinum Shortfall
There may be a 355,000-ounce platinum deficit this year following South Africa’s “labor spring,” greater than the 112,000-ounce shortfall estimated previously, the SBG analysts said. South Africa may produce 4.1 million ounces, its lowest volume of primary platinum this millennium, they said.
Prior to the wave of strikes, platinum companies were already contending with overcapacity, rising costs and falling prices. Aquarius Platinum Ltd., the fourth-largest producer, shut most of its mines in South Africa before the latest labor action. Anglo American Plc said in February it would review its Anglo American Platinum unit as returns fell short of forecasts.
The Congress of South African Trade Unions and the National Union of Mineworkers will support wage demands of as much as 21,500 rand ($2,572) a month, Cosatu Secretary-General Zwelinzima Vavi said today. That’s almost double the amount in 2010, when annual wages for South Africa’s 498,140 mine workers averaged 149,006 rand, the Chamber of Mines’ website shows.
Gold Strikes
The strikes that began in the platinum industry have also spread to gold mines, with AngloGold Ashanti Ltd. and Gold Fields Ltd. among companies reporting walkouts.
“There is no doubt in the world that the agreements in platinum will result in job losses” and posts may also be lost at AngloGold, Mark Cutifani, chief executive officer of the Johannesburg-based company, said in an interview on Talk Radio 702.
Strikes that have “ravaged” South African mining will probably increase across the precious-metals industry and may persist “well into 2013,” SBG said.
The six-member FTSE/JSE Africa Platinum Mining Index has fallen 22 percent this year. That compares with a 1.5 percent decline in the FTSE/JSE Africa Mining Index.
CALVF - Opportunities in mining shares -
BPOP. Declares Dividends on Preferred Stock, Announces Distribution on Trust Preferred Securities
http://ih.advfn.com/p.php?pid=nmona&article=54422071
ATHX~ in here 1.36
Athersys Presents Research Progress in Its Multiple Sclerosis Program
Preclinical Results Suggest that Stem Cell Treatment Could Benefit Multiple Sclerosis Patients
Oct 5, 2012 6:00:00 AM
2012 GlobeNewswire, Inc.
CLEVELAND, Oct. 5, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today it is presenting new research results at the Second Midwest Conference on Stem Cell Biology & Therapy at Oakland University in Rochester, Michigan, that highlight the potential for MultiStem®, its proprietary adult stem cell therapy, to treat multiple sclerosis (MS).
The work conducted by Athersys scientists, in collaboration with Robert Miller, Ph.D. and other scientists from Case Western Reserve University School of Medicine, and with the support of Fast Forward, a subsidiary of the National Multiple Sclerosis Society, demonstrates the potential benefits of MultiStem therapy for treating MS. In standard preclinical models of MS, researchers observed that MultiStem administration results in sustained behavioral improvements, arrests the demyelination process that is central to the pathology of MS, and supports remyelination of affected axons.
"MultiStem therapy has shown promise in treating multiple disease indications in the neurological and inflammatory and immune disease areas," said Robert Mays, Ph.D., Head of Neuroscience at Athersys. "Multiple sclerosis presents as a neurological disorder, but a central component underlying the disease is immune system dysfunction. The results of our latest preclinical studies confirm that the immunomodulatory and regenerative properties of MultiStem therapy could have relevance for treatment of this disease."
In preclinical experiments, rodents were given either an intravenous injection of MultiStem cells or placebo after the onset of symptoms in an MS model. The rodents treated with MultiStem displayed sustained and statistically significant improvement in functional testing compared to placebo treated animals. This functional improvement correlated with a statistical decrease in demyelinated lesions in the nervous system of cell treated animals compared to placebo as well as increased remyelination in cell treated animals, and this result has been confirmed in a second animal model of MS, suggesting that MultiStem treatment may accelerate the process of axonal remyelination.
"Long-term successful treatment of demyelinating diseases, such as MS, will likely require both the regulation of the immune system and the promotion of remyelination to protect axonal integrity," said Robert Miller, Ph.D., Vice President for Research and Technology Management at Case Western Reserve University. Miller also serves as Director of the Center for Translational Neuroscience at the university's School of Medicine. "I am pleased that the most recent studies suggest that MultiStem treatment influences both aspects of the disease, which means it has great potential as an attractive therapeutic option."
In 2011, Athersys and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, announced an alliance to fund the development of MultiStem for the treatment of MS, including treatment of chronic progressive forms of the disease. Fast Forward committed up to $640,000 to fund the advancement of the program to the clinical development stage.
About MS
MS is a chronic, unpredictable neurological disease that affects the central nervous system. It is thought to be an autoimmune disorder, meaning the immune system incorrectly attacks healthy tissue. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. These problems may be permanent or may come and go. According to the National MS Society, at least 400,000 Americans have MS, and every hour someone is newly diagnosed. MS affects about 2.1 million people worldwide.
(super-cross/100day) FHCO has declared a quarterly cash dividend of $0.06 per share. The dividend is payable November 7, 2012 to stockholders of record as of October 31, 2012. In January, 2010, the Company announced the initiation of a cash dividend program and has subsequently paid eleven consecutive quarterly dividends.
http://finance.yahoo.com/news/female-health-company-declares-4th-123000749.html
No iHub mod.
Wind Beneath my Wings. [Bette Midler]
MNKD. MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA
http://finance.yahoo.com/news/mannkind-completes-patient-recruitment-two-100000278.html
ANGO. AngioDynamics Awarded GPO Contract for Vascular Access Products
Contract With HealthTrust Covers Chronic & Acute Dialysis Catheters
http://finance.yahoo.com/news/angiodynamics-awarded-gpo-contract-vascular-100000569.html
ZIOP. ZIOPHARM Oncology to Present at the 11th Annual BIO Investor Forum
http://finance.yahoo.com/news/ziopharm-oncology-present-11th-annual-101000773.html
looks ok but I sure prefer much more volume/liquidity
ARQL~ glad that ones on the list! I think its going to break 3 smackerz tomorrow.
Have a good evening everybody.
This before the broadcast. "After Hours"/iBox. Zuckerberg.
Zuckerberg interview.
XNPT. XenoPort Reports Favorable Metabolism and Pharmacokinetics of XP23829, a Novel Fumaric Acid Ester, in Phase 1 Trial
Intends to Advance Development for Potential RRMS and/or Psoriasis Treatment
http://finance.yahoo.com/news/xenoport-reports-favorable-metabolism-pharmacokinetics-200000055.html
MEDW. Mediware Receives Updated FDA Clearance for Core Blood Products
http://finance.yahoo.com/news/mediware-receives-updated-fda-clearance-190000967.html
Well I found a Nooner and couldn't pass it up.
iBox.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
564
|
Created
|
09/23/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |